Growth rate and growth hormone response to growth hormonereleasing hormone challenge in slowly growing children during chronic administration of clonidine
| Autor: | L. Cinquanta, N. Padovano, G. Lombardi, Bartolomeo Merola, Veronica Esposito, Franco Orio, A. Colao, Francesco Orio, S Longobardi, Eugenio Rossi |
|---|---|
| Přispěvatelé: | Orio, Francesco, N., Padovano, L., Cinquanta, Colao, Annamaria, Merola, Bartolomeo, S., Longobardi, Rossi, Elvira, V., Esposito, F., Orio, Lombardi, Gaetano |
| Rok vydání: | 1995 |
| Předmět: |
Male
Agonist medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism medicine.medical_treatment Growth Peptide hormone Growth Hormone-Releasing Hormone Placebo Placebos Basal (phylogenetics) Endocrinology GHRH CLONIDINE Age Determination by Skeleton Internal medicine Humans Medicine Growth rate Insulin-Like Growth Factor I Child business.industry Growth factor Body Height GH Clonidine Growth Hormone Female business medicine.drug Hormone |
| Zdroj: | Journal of Endocrinological Investigation. 18:63-67 |
| ISSN: | 1720-8386 0391-4097 |
| DOI: | 10.1007/bf03349701 |
| Popis: | In this study the effects of chronic administration of clonidine, an α-2-adrenergic agonist, on the growth rate and GH response to GHRH in 12 “slowly growing” children were reported. Clonidine was administered at the dose of 0.04 mg/m2 body surface twice daily along 12 months. The protocol of the study consisted in five periods of growth rate, insulin-like growth factor-1, basal and GHRH-stimulated GH level evaluation: 1) 6-month pretreatment (P1); 2) 6-month placebo administration (P0); 3) after 4 months of therapy (P1); 4) after 4 months of clonidine withdrawal (P2); 5) after 4 months of therapy reinstatement (P3). No difference was observed between P-1 and P0 when all the parameters were considered. During P1 a significant increase of linear growth (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink